drugset / Trial / NCT05280418

Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma

NCT05280418

Phase 3 Completed 27 enrolled McMaster University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In adult patients with uncontrolled moderate-to-severe asthma, blocking TSLP with tezepelumab will improve ventilation heterogeneity (evaluated by hyperpolarized 129Xe MRI), and this will be associated with reduced airway inflammation (evaluated by sputum composition), luminal narrowing and plugging (evaluated by CT).

Timeline

Start
2022-11-08
Primary completion
2025-11-05
Completion
2025-12-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tezepelumab Monoclonal antibody 210 mg Subcutaneous

Indications